Foresee Pharmaceuticals Co., Ltd. (TPEX:6576)

Market Cap	12.56B
Revenue (ttm)	519.61M
Net Income (ttm)	-1.23B
Shares Out	157.54M
EPS (ttm)	-8.13
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	81,521
Average Volume	343,328
Open	79.30
Previous Close	79.90
Day's Range	78.40 - 80.60
52-Week Range	57.70 - 93.70
Beta	0.60
RSI	54.74
Earnings Date	Nov 10, 2025

About Foresee Pharmaceuticals

Foresee Pharmaceuticals Co., Ltd. operates as biopharmaceutical company in the United States, China, and Europe. The company’s stabilized injectable formulation pipeline includes FP-001, which completed Phase III clinical study for the treatment of advanced stage prostate cancer; FP-004 that is in preclinical stage to treat opioids use disorder; FP-011 and FP-014, a long-acting sustained release dosage form for the treatment of breast cancer/prostate cancer; and FP-016 for the treatment of neurological diseases. Its new chemical entity pipeline...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2013
• Employees: 15
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6576

Financial Performance

In 2024, Foresee Pharmaceuticals's revenue was 418.69 million, an increase of 114.67% compared to the previous year's 195.04 million. Losses were -1.08 billion, 4.32% more than in 2023.